GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (FRA:LWK) » Definitions » PensionAndRetirementBenefit

eFFECTOR Therapeutics (FRA:LWK) PensionAndRetirementBenefit : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics PensionAndRetirementBenefit?

eFFECTOR Therapeutics's PensionAndRetirementBenefit for the quarter that ended in Mar. 2024 was €0.00 Mil.


eFFECTOR Therapeutics PensionAndRetirementBenefit Historical Data

The historical data trend for eFFECTOR Therapeutics's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics PensionAndRetirementBenefit Chart

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PensionAndRetirementBenefit
- - - -

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

eFFECTOR Therapeutics PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


eFFECTOR Therapeutics Business Description

Traded in Other Exchanges
Address
142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).

eFFECTOR Therapeutics Headlines

No Headlines